← Back to Search

CAR T-cell Therapy

GLYCAR T cells for Liver Cancer (GLYCAR Trial)

Phase 1

Waitlist Available

Led By Tannaz Armaghany, M.D.

Research Sponsored by Baylor College of Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 15 years

Awards & highlights

GLYCAR Trial Summary

This trial enrolls patients with a type of cancer that arises from the liver and has come back after standard treatment, has spread outside of the liver, or the patient cannot receive standard treatment. This research study uses special immune system cells called GLYCAR T cells, a new experimental treatment.

Eligible Conditions

Liver Cancer

GLYCAR Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 15 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~15 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 15 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Patients with Dose Limiting Toxicity

Secondary outcome measures

Median T cell persistence

Percent of Patients with best response as either complete remission or partial remission

GLYCAR Trial Design

1Treatment groups

Experimental Treatment

Group I: GLYCAR T cells + Fludarabine and CytoxanExperimental Treatment3 Interventions

GPC3-CAR (GLYCAR T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with hepatocellular carcinoma.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

GLYCAR T cells

2019

Completed Phase 1

~10

Cytoxan

2007

Completed Phase 3

~1460

Fludarabine

2012

Completed Phase 3

~1100

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Baylor College of MedicineLead Sponsor

1,001 Previous Clinical Trials

6,002,243 Total Patients Enrolled

4 Trials studying Liver Cancer

5,558 Patients Enrolled for Liver Cancer

Center for Cell and Gene Therapy, Baylor College of MedicineOTHER

111 Previous Clinical Trials

2,808 Total Patients Enrolled

3 Trials studying Liver Cancer

58 Patients Enrolled for Liver Cancer

The Methodist Hospital Research InstituteOTHER

271 Previous Clinical Trials

80,366 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What detrimental effects have been found with the use of GLYCAR T cells?

"The safety of GLYCAR T cells has been assigned a rating of 1, as it is still in its initial testing phase and limited data exists to support both efficacy and security."

Answered by AI

What pathologies is GLYCAR T cells typically deployed to combat?

"GLYCAR T cells is a widely used treatment for multiple sclerosis. In addition, it has been shown to be effective in treating mixed-cell type lymphoma, leukemia, myelocytic, acute and retinoblastoma cases."

Answered by AI

How many participants are eligible to join this experiment?

"Currently, this clinical trial is not enlisting any participants. It was initially made available on March 28th 2019 and last updated on February 13th 2022. If you are considering other studies, there are 2,607 trials looking for liver cancer patients and 889 GLYCAR T cell investigations actively recruiting."

Answered by AI

Are there any vacancies for this clinical experiment currently?

"Sadly, according to the clinicaltrials.gov website, this particular trial is no longer actively recruiting patients. It was originally posted on March 28th 2019 and updated most recently on February 13th 2022; however there are still 3496 other studies which presently require volunteers."

Answered by AI

Are there any reports of prior trials involving GLYCAR T cells?

"Currently, 889 GLYCAR T cell studies are running worldwide, with 161 of those trials in Phase 3. Although the majority of these medical experiments take place in Philadelphia, Pennsylvania; there is an expansive network of 28443 sites providing such treatments."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)

Tannaz Armaghnay 2019. "Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02905188.